Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after Lung transplantation

被引:47
|
作者
Yazdani, Arash [1 ]
Singer, Lianne G. [2 ]
Strand, Vibeke [3 ]
Gelber, Allan C. [4 ]
Williams, Laura [5 ]
Mittoo, Shikha [1 ]
机构
[1] Univ Toronto, Div Rheumatol, Toronto, ON, Canada
[2] Univ Toronto, Dept Med, Toronto, ON, Canada
[3] Stanford Univ, Sch Med, Div Rheumatol Immunol, Palo Alto, CA 94304 USA
[4] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[5] Northern Ontario Sch Med, Greater Sudbury, ON, Canada
来源
关键词
lung; interstitial; rheumatoid arthritis; transplantation; survival; HISTOPATHOLOGIC PATTERN; INTERNATIONAL-SOCIETY; PULMONARY-FIBROSIS; SYSTEMIC-SCLEROSIS; HEART; SCLERODERMA; CANDIDATES; PNEUMONIA; PROGNOSIS; SF-36;
D O I
10.1016/j.healun.2014.01.858
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Patients with rheumatoid arthritis associated interstitial lung disease (RA-ILD) have increased mortality with limited treatment options. We set out to examine post-transplant survival in RA-ILD patients compared with patients with idiopathic pulmonary fibrosis (IPF) and scleroderma-associated ILD (SSc-ILD). We also describe post-transplant quality of life (QoL) outcomes in RA-ILD. METHODS: A retrospective review was performed on lung transplantation (1989 to 2011) among patients with RA-ILD, IPF (group-matched for age and transplant year) and SSc-ILD. Cumulative survival after transplantation was estimated by the Kaplan-Meier method and compared between groups using the log-rank test. The 36-item Medical Outcomes Survey Short Form (SF-36) and the St. George's Respiratory Questionnaire (SGRQ) scores, before and after lung transplantation, were analyzed. RESULTS: Overall, 10 patients with RA-ILD, 53 with IPF and 17 with SSc-ILD underwent lung transplantation with ages (mean +/- SD) of 59.4 +/- 5.6, 61.0 +/- 4.0 and 45.4 +/- 12.7 years, respectively. Cumulative survival rates at 1-year post-transplant for the RA-ILD, IPF and SSc-ILD groups were 67%, 69% and 82%, respectively, and there was no significant difference among groups in age- and gender-adjusted analyses. Among the RA-ILD patients, mean SF-36 physical component summary scores improved from 22.4 +/- 8.1 to 32.2 +/- 12.9 (p = 0.1), SF-36 mental component summary scores improved from 44.7 +/- 15.3 to 54.9 +/- 4.8 (p = 0.19) and SGRQ total scores improved from 70.4 +/- 16.1 to 36.0 +/- 18.5 (p = 0.03). CONCLUSIONS: After lung transplantation, RA-ILD and IPF patients have similar survival rates. Further, in RA-ILD patients, lung transplantation appears to result in a significant improvement in QoL with regard to respiratory symptoms. These data suggest that lung transplantation should be considered in patients with end-stage RA-ILD. (C) 2014 International Society for Heart and Lung Transplantation. All rights reserved.
引用
收藏
页码:514 / 520
页数:7
相关论文
共 50 条
  • [41] Effectiveness and tolerability of antifibrotics in rheumatoid arthritis-associated interstitial lung disease
    Juge, Pierre-Antoine
    Hayashi, Keigo
    McDermott, Gregory C.
    Vanni, Kathleen M. M.
    Kowalski, Emily
    Qian, Grace
    Bade, Katarina
    Saavedra, Alene
    Dieude, Philippe
    Dellaripa, Paul F.
    Doyle, Tracy J.
    Sparks, Jeffrey A.
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2024, 64
  • [42] Impact of radiological honeycombing in rheumatoid arthritis-associated interstitial lung disease
    Yamakawa, Hideaki
    Sato, Shintaro
    Nishizawa, Tomotaka
    Kawabe, Rie
    Oba, Tomohiro
    Kato, Akari
    Horikoshi, Masanobu
    Akasaka, Keiichi
    Amano, Masako
    Sasaki, Hiroki
    Kuwano, Kazuyoshi
    Matsushima, Hidekazu
    BMC PULMONARY MEDICINE, 2020, 20 (01)
  • [43] Peripheral Biomarker Signatures in Rheumatoid Arthritis-Associated Interstitial Lung Disease
    Wheeler, Austin M.
    Baker, Joshua F.
    Riley, Thomas R.
    Johnson, Tate M.
    Yang, Yangyuna
    Roul, Punyasha
    Wysham, Katherine D.
    Cannon, Grant W.
    Kunkel, Gary
    Kerr, Gail
    Ascherman, Dana P.
    Monach, Paul
    Reimold, Andreas
    Matson, Scott
    Poole, Jill A.
    Duryee, Michael J.
    Thiele, Geoffrey M.
    Mikuls, Ted R.
    England, Bryant R.
    ARTHRITIS & RHEUMATOLOGY, 2025,
  • [44] Overview of Rheumatoid Arthritis-Associated Interstitial Lung Disease and Its Treatment
    Pugashetti, Janelle Vu
    Lee, Joyce S.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 45 (03) : 329 - 341
  • [45] Moving forward in Rheumatoid Arthritis-Associated Interstitial Lung Disease Screening
    Narvaez, Javier
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (18)
  • [46] Peripheral Blood Biomarkers Of Rheumatoid Arthritis-Associated Interstitial Lung Disease
    Chen, Juan
    Ascherman, Dana P.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S174 - S174
  • [47] Treatment with Etanercept in a Patient with Rheumatoid Arthritis-Associated Interstitial Lung Disease
    Wang, Yu
    Xu, Sheng-qian
    Xu, Jian-hua
    Ding, Changhai
    CLINICAL MEDICINE INSIGHTS-CASE REPORTS, 2011, 4 : 49 - 52
  • [48] Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review
    Iqbal, Kundan
    Kelly, Clive
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2015, 7 (06) : 247 - 267
  • [49] Are risk predicting models useful for estimating survival in rheumatoid arthritis-associated interstitial lung disease?
    Nurmi, Hanna
    Purokivi, Minna
    Karkkainen, Miia
    Kettunen, Hannu-Pekka
    Selander, Tuomas
    Kaarteenaho, Riitta
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [50] ANALYSIS OF GUT MICROBIOTA IN RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
    Ruiz-Limon, P.
    Mena-Vazquez, N.
    Moreno-Indias, I.
    Manrique Arija, S.
    Lisbona, J. M.
    Cano Garcia, L.
    Redondo, R.
    Tinahones, F. J.
    Fernandez-Nebro, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 824 - 825